Nereus (tradipitant) is a newly FDA‑approved oral neurokinin‑1 (NK‑1) receptor antagonist indicated for the prevention of vomiting induced by motion sickness in adults, representing the first new pharmacologic option for this condition in over 40 years; it works by selectively blocking substance P–mediated activation of NK‑1 receptors in the brain to reduce motion‑induced vomiting, and in Phase 3 trials significantly lowered vomiting rates versus placebo when taken about an hour before motion exposure, with common side effects including somnolence, headache, and fatigue.